Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Pharmacyte Biotech Inc (PMCB)

Pharmacyte Biotech Inc (PMCB)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 67,923
  • Shares Outstanding, K 1,391,871
  • Annual Sales, $ 0 K
  • Annual Income, $ -4,070 K
  • 60-Month Beta 2.10
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm 0.00
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 03/12/20
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.0382 +42.67%
on 01/06/20
0.0565 -3.54%
on 01/09/20
+0.0135 (+32.93%)
since 12/20/19
3-Month
0.0318 +71.38%
on 12/10/19
0.0690 -21.01%
on 12/12/19
+0.0196 (+56.16%)
since 10/22/19
52-Week
0.0318 +71.38%
on 12/10/19
0.0690 -21.01%
on 12/12/19
+0.0154 (+39.39%)
since 01/22/19

Most Recent Stories

More News
PharmaCyte Biotech Successfully Completes All Release Tests on Clinical Trial Product

PharmaCyte Biotech, Inc. (OTCQB: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box(R),...

PMCB : 0.0545 (+11.68%)
PharmaCyte Biotech Addressing Unmet Need in Patients with LAPC as Pancreatic Cancer 5-Year Survival Rate Increases to 10%

This month the American Cancer Society announced that for the first time ever, the 5-year survival rate for pancreatic cancer has reached double digits. While this is certainly good news, the increase...

PMCB : 0.0545 (+11.68%)
PharmaCyte Biotech Set to Reach Three Major Milestones in 2020

PharmaCyte Biotech's (OTCQB: PMCB) shareholders should expect 2020 to be the year that ushers in a host of much-anticipated milestones. This year the company's therapy for locally advanced, inoperable...

PMCB : 0.0545 (+11.68%)
PharmaCyte Biotech Passing All Completed Tests on Clinical Trial Product

PharmaCyte Biotech, Inc. (OTCQB: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box(R),...

PMCB : 0.0545 (+11.68%)
PharmaCyte Biotech Provides Details on Quarterly Shareholder Update

PharmaCyte Biotech, Inc. (OTCQB: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box(R),...

PMCB : 0.0545 (+11.68%)
PharmaCyte Biotech Finalizes Pancreatic Cancer Treatment for U.S. FDA Approval to Begin Clinical Trial

PharmaCyte Biotech (OTCQB: PMCB) has a clinical trial product, a clinical trial protocol, including a clinical trial design, a Principal Investigator, and the company is ready to present its treatment...

PMCB : 0.0545 (+11.68%)
PharmaCyte Biotech to Hold Quarterly Shareholder Update

PharmaCyte Biotech, Inc. (OTCQB: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box(R),...

PMCB : 0.0545 (+11.68%)
PharmaCyte Biotech "Release Testing" Successful on All Completed Tests of Clinical Trial Product

PharmaCyte Biotech, Inc. (OTCQB: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box(R),...

PMCB : 0.0545 (+11.68%)
PharmaCyte Biotech Successfully Completes Final Manufacturing Run of Clinical Trial Product

PharmaCyte Biotech, Inc. (OTCQB: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box(R),...

PMCB : 0.0545 (+11.68%)
PharmaCyte Biotech's "Release Testing" Last Critical Event Before Submission of Investigational New Drug Application

PharmaCyte Biotech (OTCQB: PMCB) has reduced a long list of FDA-required items to just one last important component--release testing--before it can submit an Investigational New Drug application (IND)...

PMCB : 0.0545 (+11.68%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Strongest short term outlook on maintaining the current direction.

See More Share

Trade PMCB with:

Key Turning Points

2nd Resistance Point 0.0609
1st Resistance Point 0.0577
Last Price 0.0545
1st Support Level 0.0485
2nd Support Level 0.0425

See More

52-Week High 0.0690
Fibonacci 61.8% 0.0548
Last Price 0.0545
Fibonacci 50% 0.0504
Fibonacci 38.2% 0.0460
52-Week Low 0.0318

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar